Core Viewpoint - The company expects a significant increase in revenue for the year 2025, projecting total revenue of 447 million yuan, driven by effective production planning and strong market demand for its medical consumables and intelligent equipment [1] Group 1: Revenue and Profitability - For the year 2025, the company anticipates a substantial growth in overall revenue, primarily due to the orderly implementation of production plans and the dual focus on technological innovation and process iteration [1] - In the first three quarters of 2025, the company's main revenue reached 225 million yuan, reflecting a year-on-year increase of 2.31% [2] - The net profit attributable to the parent company for the first three quarters was 8.84 million yuan, up 15.82% year-on-year [2] - The company expects to turn a profit in net profit attributable to the parent company and net profit after deducting non-recurring gains and losses, mainly due to the increase in operating revenue [1] Group 2: Market Performance and Product Development - The blood purification and medical-device combination intelligent equipment business has shown good development, particularly benefiting from strong demand growth in the terminal market for medical consumables [1] - The company is focusing on new product development and market expansion around the medical-device combination intelligent equipment, which has seen significant revenue growth [1] - In Q3 2025, the company's single-quarter main revenue was 83.64 million yuan, representing a year-on-year increase of 54.38% [2] Group 3: Financial Metrics - The company's debt ratio stands at 29.86%, indicating a moderate level of financial leverage [2] - The gross profit margin for the company is reported at 40.19%, reflecting healthy profitability [2] - Investment income for the company was 167,600 yuan, while financial expenses were reported at -523,600 yuan [2]

迈得医疗(688310.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润与上年同期(法 定披露数据)相比，将实现扭亏为盈，实现归属于母公司所有者的净利润6652.13万元左右。 ...

智通财经APP讯，迈得医疗(688310.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润与上年同期(法定披露数据)相比，将实现扭亏为盈，实现归属于母公司所有者的净利润6652.13万元 左右。 ...

Core Viewpoint - The company, Maide Medical, is expected to turn a profit in 2025, projecting a net profit of approximately 66.52 million yuan, a significant improvement compared to the previous year [1] Group 1: Financial Performance - The company anticipates a substantial increase in overall operating revenue for the year 2025 [1] - The projected net profit of 66.52 million yuan marks a turnaround from previous losses [1] Group 2: Business Drivers - The growth in revenue is attributed to the orderly implementation of production plans, ensuring effective product delivery [1] - The company emphasizes dual drivers of technological innovation and process iteration to enhance product competitiveness and market influence [1] - The blood purification and medical device combination intelligent equipment sectors are performing well, particularly due to strong demand growth in the terminal market for medical consumables [1] Group 3: Market Outlook - The company is optimistic about the market demand for medical device combination intelligent equipment and is focusing on new product development and market expansion in this area [1] - Significant revenue growth has been achieved in the medical device combination intelligent equipment segment [1]

Core Viewpoint - The company, Maide Medical (688310.SH), is expected to achieve significant revenue growth in 2025, with projected revenue of approximately 447 million yuan, representing an increase of about 173 million yuan or 62.81% year-on-year [1] Financial Performance - The company anticipates turning a profit in 2025, with a projected net profit attributable to shareholders of approximately 66.52 million yuan [1] - The expected net profit, excluding non-recurring gains and losses, is around 54.64 million yuan [1] Business Growth Drivers - The substantial revenue growth is attributed to the orderly implementation of production plans, ensuring effective product delivery [1] - The company emphasizes technological innovation and process iteration to enhance product competitiveness and market influence [1] - The blood purification and medical device combination intelligent equipment sectors are performing well, particularly due to strong demand growth for medical consumables in the end market [1] - The optimistic market outlook for medical device combination intelligent equipment has led the company to focus on new product development and market expansion in this area [1]

证券代码：688310 证券简称：迈得医疗 公告编号：2026-007 迈得医疗工业设备股份有限公司 二、上年同期业绩情况和财务状况 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计迈得医疗工业设备股份有限公司（以下简称"公 司"）2025 年年度实现营业收入 44,749.77 万元左右，与上年同期（法定披露数 据）相比，将增加 17,264.69 万元左右，同比增加 62.81%左右。 2、预计 2025 年年度实现归属于母公司所有者的净利润与上年同期（法定披 露数据）相比，将实现扭亏为盈，实现归属于母公司所有者的净利润 6,652.13 万元左右。 3、预计 2025 年年度实现归属于母公司所有者扣除非经常性损益的净利润 5,463.95 万元左右。 （三）本次业绩预告未经注册会计师审计。 （一）利润总额：-2,923.18 万元。 归 ...

迈得医疗公告称，2025年年度预计实现营业收入44,749.77万元左右，同比增加62.81%左右。预计实现 归属于母公司所有者的净利润6,652.13万元左右，上年同期为 -1,998.12万元，实现扭亏为盈；预计扣非 净利润5,463.95万元左右。本期营收大幅增长得益于公司推进生产计划、强化技术创新，血液净化和药 械组合类智能装备业务发展良好，尤其药械组合类智能装备收入增长较大。净利润扭亏为盈主要因营收 增长。 ...

Trading Information - On January 23, 2026, Maide Medical (688310) closed at 16.52 yuan, up 1.1%, with a turnover rate of 1.15%, trading volume of 19,100 shares, and a transaction amount of 31.426 million yuan [1] - On the same day, the net outflow of main funds was 2.8628 million yuan, while retail investors saw a net inflow of 4.737 million yuan [3] Company Announcements - Maide Medical's fifth board of directors held its ninth meeting on January 22, 2026, where it approved a proposal to provide financial assistance to its subsidiary, Maide Shun, not exceeding 100 million yuan, with a loan term of up to three years and interest rates based on the one-year LPR [1][2] - The company will hold its first extraordinary general meeting of 2026 on February 9, 2026, to review the financial assistance proposal, which involves related shareholders abstaining from voting and separate counting for minority investors [1][2] - The financial assistance transaction has been approved by the board and relevant committees but is subject to shareholder approval [2]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月23日收盘，迈得医疗（688310）报收于16.52元，较上周的16.15元上涨2.29%。本周，迈 得医疗1月20日盘中最高价报16.72元。1月19日盘中最低价报16.06元。迈得医疗当前最新总市值27.46亿 元，在自动化设备板块市值排名74/78，在两市A股市值排名4844/5182。 迈得医疗工业设备股份有限公司第五届董事会第九次会议于2026年1月22日召开，审议通过《关于向控 股子公司提供财务资助暨关联交易的议案》，同意公司以自有资金向控股子公司浙江迈得顺隐形眼镜有 限公司提供不超过人民币10,000万元的财务资助。资助期限为自股东会审议通过之日起3年内，借款利 率参照合同签订日前1个工作日的一年期LPR，利息按实际借款天数计算，额度内可循环使用。 迈得顺少数股东未同比例提供资助，关联人林军华、陈万顺为本次资助提供连带责任保证。该交易构成 关联交易，已获董事会及相关委员会审议通过，尚需提交股东会审议。公司表示风险可控，不影响正常 经营。 迈得医疗定于20 ...

Group 1 - The company, Maide Medical, held its fifth board meeting on January 22, 2026, to discuss the proposal for the first extraordinary shareholders' meeting of 2026 [1] Group 2 - Local state-owned assets have begun purchasing auctioned properties, acquiring over 60 units in the Nansha District of Guangzhou at prices around 6,000 to 7,000 yuan per unit, while the average listing price for second-hand homes in the same community exceeds 20,000 yuan [1]